| Today's Top Story |  |  | | - Booz: Pharma should take individual approach to emerging markets
A new analysis from consultant Booz & Co. notes that emerging markets may not be as lucrative for pharmaceutical companies as they hope. While pharma companies that enter these markets early can help shape them, the report noted that the size of countries classified as "emerging markets" varies, and the "ambitious targets" of some companies have not been met. "Companies should be aware that whilst there is huge potential here, variations within the emerging markets themselves require different and tailored approaches," the report cautions. PharmaTimes (U.K.) (3/28)       | Health Care & Policy | | | | - Pfizer's leukemia drug Bosulif wins conditional EU approval
Pfizer obtained conditional approval from the European Commission to market Bosulif, or bosutinib, for adults with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors, who can't take imatinib, nilotinib and dasatinib. The approval was based on positive data from a Phase I/II trial involving more than 500 Ph+CML patients. Pharmaceutical Business Review Online (3/29) - Novartis chief: Genomics will drive growth in oncology
 Oncology and regenerative medicine will be among the top growth areas in drug development over the next five to 10 years, Novartis CEO Joe Jimenez said in this interview. The explosion of technologies such as human genome sequencing has generated a wealth of data that will allow drugmakers to discover and develop innovative medicines, he said. CNNMoney/Fortune (3/21) - Amniotic fluid stem cells may treat necrotizing enterocolitis
 A study in the journal Gut suggests that stem cells from amniotic fluid could help repair damage resulting from necrotizing enterocolitis, the decay of the intestinal lining in premature or ill infants. "Although amniotic fluid stem cells have a more limited capacity to develop into different cell types than those from the embryo, they nevertheless show promise for many parts of the body including the liver, muscle and nervous system," said lead investigator Dr. Paolo De Coppi of the University College London Institute of Child Health. The research involved rat models. MedicalDaily.com (3/25) | Company & Financial News | | | | | Food & Agriculture | | | | - Ill. farm group opposes biotech labeling proposal
The Illinois Farm Bureau has spoken out against a bill from state Sen. Dave Koehler, D-Peoria, to require firms to label products that contain biotech ingredients. The proposal could stigmatize biotech crops, the group said. Summer hearings are expected on the bill. Brownfield (3/26) | Industrial & Environmental | | | | - Moody's: Maintaining RFS may prompt refiners to use more biofuels
U.S. refiners may invest more in biofuels if their targets under the Renewable Fuel Standard are not reduced, according to a report by ratings agency Moody's. "In the absence of any [Environmental Protection Agency] waivers to meeting the renewable fuel requirements, we expect refiners to increase their investments in blending logistics infrastructure, ethanol production facilities and renewable fuels technology," Moody's said. Other options for refiners would be to increase gasoline exports to avoid buying RINs or to pass on the cost of RIN exposure to consumers, Moody's said. Platts (3/27)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | It is impossible to live pleasurably without living prudently, and honorably, and justly; or to live prudently, and honorably, and justly, without living pleasurably."
--Epicurus,
Greek philosopher  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, March 28, 2013
- Wednesday, March 27, 2013
- Tuesday, March 26, 2013
- Monday, March 25, 2013
- Friday, March 22, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment